Juvenile Arthritis News

ATLANTA — An intervention bundle reminding patients with rheumatoid arthritis and juvenile idiopathic arthritis of the benefits of influenza vaccination was associated with improved vaccine coverage, according to findings presented at ACR/ARP 2019.

ATLANTA — Patients with juvenile dermatomyositis demonstrate obvious mitochondrial abnormalities in the tissue and periphery, supporting the use of anti-mitochondrial antibodies as a prognostic marker, according to data presented at ACR/ARP 2019.

ATLANTA — Results of a double-blind, randomized, placebo-controlled trial showed a clear benefit of tofacitinib in controlling disease flares in juvenile idiopathic arthritis, according to a speaker at ACR/ARP 2019.

ATLANTA — Children with Down syndrome are at an increased risk for arthritis at a rate that is two to three times higher than previously reported, according to data presented here. However, diagnosis is often delayed for myriad reasons.

The FDA has approved Abrilada, a biosimilar to Humira, making it the fifth biosimilar to the reference drug and 25th biosimilar overall to gain approval in the United States, according to an agency press release.

ATLANTA — Limited knowledge about inactivated vaccines, misconceptions and fears, as well as long wait times and accessibility issues are among the leading drivers of influenza vaccine hesitancy among adults with rheumatoid arthritis and juvenile idiopathic arthritis, according to a presenter at ACR/ARP 2019.

Children with either inflammatory bowel disease, chronic noninfectious osteomyelitis or juvenile idiopathic arthritis developed psoriasis at an increased rate compared with the general public, with the highest rates seen among those treated with TNF inhibitors, according to data published in Arthritis Care & Research.

Acute digital clubbing was one clinical characteristic of a rare and potentially fatal lung disease recently observed in a cohort of patients with systemic juvenile idiopathic arthritis, according to findings published in Annals of the Rheumatic Diseases.

Rheumatology patients treated with interleukin inhibitors have an increased risk for serious infections, opportunistic infections and cancer, according to data published in JAMA Open Network.

Adults with a history of juvenile arthritis carry a greater risk for coronary artery disease compared with those without arthritis, according to data published in Arthritis Care & Research.